ÐÂÎÅ×ÊѶ
Z6ÈËÉú¾ÍÊDz©´´ÐÂÒ©Ñз¢ÔÙÍ»ÆÆ£¬WP103ÓÐÍûÌî²¹ÐÂÉú¶ùHIEÖÎÁƵÄÁÙ´²ÐèÇó£¡È«Çò·¶Î§²»¿É¶àµÃ»ñFDAË«È϶¨µÄÒ©Æ·£¬ÔÙ»ñINDÉêÇëÊÜÀí£¡
ÈÕÆÚ£º
2024Äê12ÔÂ30ÈÕ 12:52

ÃÀ¹ú¶«²¿Ê±¼ä12ÔÂ17ÈÕ£¬¹«Ë¾Ñз¢µÄ´´ÐÂÒ©ÐÂʯɼ¼î¼××¢ÉäÒº£¨WP103£©Õë¶ÔÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¨HIE£©µÄÐÂÊÊÓ¦Ö¢µÄÁÙ´²ÊÔÑ飨IND£©ÉêÇ룬»ñµÃÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ÊÜÀí£¬½øÈëרҵÉóÆÀ½×¶Î¡£
ÕâÒâζ×ÅZ6ÈËÉú¾ÍÊDz©½«ÎªÐÂÉú¶ùHIEÕâһȫÇò¼±ÐèÒ©ÎïÁÆ·¨µÄ¼²²¡£¬µì¶¨¿ªÍØÐÔÑо¿µÄ»ù´¡£»Ò²±êÖ¾×ÅZ6ÈËÉú¾ÍÊDz©¶ÔÖйúÔ´´Ò©“ʯɼ¼î¼×”ÔÚÐÂÖÆ¼Á¡¢ÐÂÊÊÓ¦Ö¢´´ÐÂÑз¢¼°²¼¾ÖÈ«ÇòÊг¡µÄÓÖÒ»´ó³É¾Í¡£
¹ØÓÚÐÂÉú¶ùȱÑõȱѪÐÔ£¨HIE£©
HIEÊÇÓÉÐÂÉú¶ùÄÔ×é֯ȱÑõºÍÄÔѪÁ÷Á¿¼õÉÙÒýÆðµÄÒ»ÖÖÐÂÉú¶ùÄÔËðÉ˼²²¡£¬¶Ô·¢ÓýÖеĴóÄÔÓÐÑÏÖØÓ°Ï죬²¢¿ÉÄܵ¼ÖÂÏÔÖøµÄËÀÍöÂʺͷ¢²¡ÂÊ¡£ÔÚÃÀ¹ú£¬HIEÿÄêÓ°Ïì´óÔ¼²»µ½10,000ÃûÓ¤¶ù£»È«Çò·¶Î§ÄÚ£¬Ã¿ÄêÔ¼75ÍòÓ¤¶ùî¾»¼ÖжȻòÖØ¶ÈHIE£¬µ¼ÖÂÔ¼400,000ÃûÓ¤¶ù»¼ÓÐÉñ¾·¢ÓýÕϰ¡£
Ŀǰ£¬ÃÀ¹úÉÐÎÞ»ñÅúÒ©ÎïÓÃÓÚÖÎÁÆÐÂÉú¶ùHIE¡£·¢´ï¹ú¼ÒÕë¶ÔÐÂÉú¶ùÖÐÖØ¶ÈHIEµÄ±ê×¼¸ÉÔ¤·½·¨Ö»ÄÜÊÇÖÎÁÆÐÔµÍΣ¨TH£©£¬µ«½ÓÊÜ TH ÖÎÁƵÄÖÐÖØHIEÐÂÉú¶ùÈÔÈ»»á¾Àú»ÙÃðÐԵIJ¢·¢Ö¢£º48%µÄËÀÍö»òÖжÈ/ÖØ¶È²Ð¼²¡£Òò´Ë£¬µ±ÐÂÉú¶ù·¢ÉúHIEʱ£¬·Ç³£¼±Ð谲ȫÓÐЧµÄÖÎÁÆ£¬²¢ÇÒ¶ÔÓÚ²»ÊÊÓÃÓÚTHµÄÇáÖ¢HIE²¡ÀýÒ²ÐèÒªÓÐЧµÄÒ©ÎïÁÆ·¨¡£
¹ØÓÚWP103Õë¶ÔHIEµÄINDÉêÇë»ñµÃÃÀ¹úFDAÊÜÀí
¹«Ë¾±¾´ÎµÄ³É¹¦µÝ½»ÓëÊÜÀí£¬ÊÇÒÔ¹«Ë¾Ñз¢Óë¼¼ÊõÍŶӿªÕ¹µÄ¸ßÖÊÁ¿¡¢·ûºÏFDAÓëICHÒªÇóµÄÁÙ´²Ç°Ò©Ñ§£¨ÔÁÏÒ©¡¢ÖƼÁ£©ºÍÒ©Àí¶¾ÀíÑо¿Êý¾ÝΪ»ù´¡¡£
¶àÏîÁÙ´²Ç°Ñо¿ÏÔʾ£¬Ê¯É¼¼î¼×ÖÎÁÆÐÂÉú¶ùHIEDZÁ¦¾Þ´ó£¬ÓÐÏ£Íûͨ¹ý×ۺϵÄ×÷ÓûúÖÆÀ´Ó¦¶ÔȱÑõȱѪµÄ²¡ÀíÉúÀíÌôÕ½£¬¸ø»¼¶ù´øÀ´ÁÙ´²»ñÒæ£¬°üÀ¨µ¨¼îˮƽÌáÉý¡¢½µµÍÐ˷ܶ¾ÐÔ¡¢¸ÄÉÆÏßÁ£Ì幦ÄÜÕϰ¡¢½µµÍÑ×Ö¢ºÍ¼õÉÙ´ÙÑ×ϸ°ûÒò×Ó (IL-6¡¢TNF-α ºÍ IL-1β)£¬½µµÍÑõ»¯Ó¦¼¤£¬ÒÔ¼°¼õÉÙÉñ¾ÔªËÀÍöµÈ¡£

±¾´ÎÁÙ´²ÊÔÑéÉêÇëµÄÊÜÀí£¬ÊÇZ6ÈËÉú¾ÍÊDz©´´ÐÂÒ©Ñз¢ÍŶÓÔÚÐÂÉú¶ùHIEÖÎÁÆÁìÓòµÄÒ»´ó½øÕ¹¡£
¹ØÓÚZ6ÈËÉú¾ÍÊDz©´´ÐÂÒ©»ñÈ«Çò·¶Î§²»¿É¶àµÃFDAË«È϶¨µÄÓÅÊÆ
¹«Ë¾ÓÚ2024Äê4Ôµ׻ñµÃFDAÊÚÓèµÄʯɼ¼î¼×ÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¨HIE£©µÄº±¼û¶ù¿Æ¼²²¡ÓÃÒ©È϶¨(rare pediatric disease designation£¬RPDD)£¬ÓÖÓÚ2024Äê5Ôµ׻ñµÃFDAÊÚÓèµÄÖÎÁÆÐÂÉú¶ùHIEµÄ¹Â¶ùÒ©È϶¨(orphan drug designation, ODD)¡£×÷ΪȫÇò·¶Î§ÄÚ²»¿É¶àµÃµÄ»ñµÃFDAË«È϶¨µÄÒ©Æ·£¬RPDDºÍODDÈ·±£Á˸ßÁÙ´²¼ÛֵDZÁ¦µÄʯɼ¼î¼×µÄ¸ßÉÌÒµ¼ÛÖµ£¬°üÀ¨£º´ÓÒ©Æ·»ñÅú¿ªÊ¼µÄ7ÄêµÄÊг¡×¨ÓªÈ¨(market exclusivity)¡¢ÐÂÒ©ÉêÇë(NDA)µÄÓÅÏÈÉóÆÀÉóÅú¡¢ÐÂÒ©NDA×¢²á·ÑÓõÄÃâ³ý(Ô¼3000ÍòÈËÃñ±Ò)£¬ÒÔ¼°ÔÚÁÙ´²¿ª·¢¹ý³ÌÖиü¶àµÄFDAµÄÖ¸µ¼ÓëÖ§³Ö£¬¹²Í¬´Ù½øHIEÕâÒ»ÑÏÖØºÍΣ¼°ÉúÃüµÄ¶ù¿Æº±¼û¼²²¡Ò©ÎïµÄÑз¢¡£
±¾´ÎÉ걨µÄÐÂÉú¶ùHIEÊÊÓ¦Ö¢£¬ÕâÒ»µ¼ÖÂÓ¤¶ùËÀÍö¡¢ÖØ´ó²Ð¼²µÄÑÏÖØ¼²²¡£¬ÃÀ¹úÉÐÎÞ»ñÅúµÄÖÎÁÆÒ©Î´æÔÚÑÏÖØµÄδÂú×ãÁÙ´²ÐèÇó¡£¹«Ë¾ÒóÇÐÏ£Íûʯɼ¼î¼×µÄÁÆÐ§ºÍ°²È«ÐÔÄܹ»¿ìËÙÔÚÁÙ´²ÉÏ»ñµÃÑéÖ¤£¬´Ó¶øÌî²¹ÐÂÉú¶ùHIEÖÎÁƵÄÈ«ÇòÁÙ´²ÐèÇó¡£ÆÚ´ý¾ÍÁÙ´²ÊÔÑéµÄÉêÇë»ñµÃFDAµÄ»ý¼«·´À¡£¬ÍƽøWP103µÄ¿ìËÙ¡¢¸ßÖÊÁ¿µÄÁÙ´²¿ª·¢£¬ÔçÈÕ½«¸üºÃµÄÁÙ´²Ñ¡Ôñ´ø¸øÈ«ÇòǧǧÍòÍòÊÜHIEÍþвµÄ»¼¶ùºÍ¼ÒÍ¥¡£
¹ØÓÚZ6ÈËÉú¾ÍÊDz©Ñз¢
Z6ÈËÉú¾ÍÊDz©Ä¿Ç°½¨ÓÐÔ¼120È˵ÄÑз¢ÍŶӣ¬Äܹ»¿ªÕ¹È«¼ÛÖµÁ´µÄÒ©Æ·Ñз¢¹¤×÷£¬´ÓÔçÆÚ·¢ÏÖµÄÉè¼Æ¡¢»¯Ñ§¡¢ÉúÎïѧ£¬µ½ IND-enablingµÄҩѧÓëÒ©Àí¶¾ÀíÑо¿£¬ÒÔ¼°ÁÙ´²¿ª·¢µÄ¹æ»®ÓëÔËÓª¡£Í¬Ê±£¬¹«Ë¾½¨ÓÐԺʿ¹¤×÷Õ¾¡¢²©Ê¿ºó¹¤×÷Õ¾¡¢Ê¡¼¶¼¼Êõ¡¢Ñз¢ÖÐÐĵȶà¸ö¸ß¶Ëƽ̨£¬ÎªÒ©Æ·Ñз¢ÌṩÐÛºñµÄÈ˲ÅÓëר¼ÒÖ§³Ö¡£
¹«Ë¾Ñз¢¹ÜÏ߷ḻ£¬ÐγÉÁË´´ÐÂÒ©Ñз¢¡¢·ÂÖÆÒ©Ñз¢¡¢ÔÁÏÒ©Ñз¢¡¢ÖÐÒ©Ñз¢ÆëÍ·²¢½øµÄ´óÑз¢ÌåϵÓë¸ñ¾Ö¡£ÆäÖУ¬´´ÐÂÒ©Ñз¢¾Û½¹£¨ÖØ´ó£©Éñ¾ÏµÍ³¼²²¡¡¢´úл¡¢×ÔÌåÃâÒß¡¢º±¼û²¡µÈËÄ´óÁìÓò£¬¼½Íû³ä·Ö·¢»Ó¹«Ë¾¶àÄêµÄÊý¾Ý»ýÀÛ£¬Îª»¼Õß´øÀ´ÁÙ´²Ø½ÐèµÄ´´ÐÂÁÆ·¨¡£
»ùÓÚ¶àÄêµÄÊý¾Ý»ýÀۺͶԴóÁ¿Êý¾ÝµÄ¶´²ì£¬Z6ÈËÉú¾ÍÊDz©´´ÐÂÒ©ÍŶÓÔÚÈ«Çò·¶Î§ÄÚÊ×´´»ñµÃʯɼ¼î¼×ÖÎÁÆÐÂÉú¶ùHIEµÄODDºÍRPDDµÄÈ϶¨£¬²¢ÔÚ¶Ìʱ¼äÄÚÍê³É¸ßÖÊÁ¿µÄÁÙ´²Ç°¹¤×÷£¬»ñµÃFDAµÄINDÁÙ´²ÊÔÑéÉêÇëÊÜÀí£¬³ä·ÖÏÔʾÁ˳¬¸ßµÄÐÂÒ©Ñз¢ÄÜÁ¦£¬ÒÔ¼°¼ÓËÙÍÆ½ø½â¾ö»¼Õߨ½ÐèµÄרҵ¾«Éñ¡£
Ïà¹ØÍÆ¼ö